Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux [1]
[edit] Mechanism of action
Triflusal is a selective platelet antiaggregant through;
- blocks cyclooxygenase inhibiting thromboxane A2, preventing aggregation
- preserves vascular prostacyclin, thus promoting anti-aggregant effect
- blocks phosphodiesterase thereby increasing cAMP concentration, thereby promoting anti-aggregant effect due to inhibition of calcium mobilization
[edit] References
- ^ Murdoch D, et al. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.Drugs 2006; 66(5):671-92
|
|
|
| Antiplatelet drugs |
|
|
| Anticoagulants |
|
|
|
|
Factor Xa inhibitors
(with some II inhibition)
|
|
|
low-molecular-weight heparin (Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin)
oligosaccharides (Fondaparinux, Idraparinux)
heparinoid ( Danaparoid, Sulodexide, Dermatan sulfate)
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
Thrombolytic drugs/
fibrinolytics |
|
|
| Non-medicinal |
|
|
|
|
|
(what is this?) (verify)
